Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06208605 · ClinicalTrials.gov registry record · NA
Innovations in Personalizing Treatment Study
A NA study of Eating Disorders, sponsored by University of Louisville.
- Recruiting
- Registry status
- NA
- Development phase
- 320
- Enrollment target
- 1
- Study location
NCT06208605: Recruiting NA study of Eating Disorders, sponsored by University of Louisville.
NCT06208605 is a NA study of Eating Disorders that is actively recruiting participants, run by University of Louisville. The registered enrollment target is 320 participants, roughly in line with the 314-participant average among 37 other Eating Disorders trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06208605, a NA study of Eating Disorders, is actively recruiting participants, sponsored by University of Louisville.
- RECRUITING
- Registry status
- NA
- Development phase
- 320 participants
- Enrollment target
- 1
- Study location
Study Summary
Eating disorders (EDs) are serious mental illness: someone dies of an ED every 52 minutes. EDs are highly related to a host of negative outcomes, including public health and individual disease burden, medical and psychological comorbidities, and social determinants of health (SDOH). Treatment response for EDs are suboptimal; there are no evidence-based treatment for adults with anorexia nervosa (AN) or Other Specified Feeding or Eating Disorder (OSFED) and only 50% of adults respond to current evidence based treatments. There are no precision treatments, nor any treatments that consider social context, in existence. Personalized treatments for EDs, that consider social contexts, are urgently needed to improve treatment response and minimize the suffering associated with these illnesses. The investigators' overall goal, extending upon their past work, is to create a treatment personalized based on idiographic (or one person) models (termed Transdiagnostic Network Informed Personalized Treatment for EDs; T-NIPT-ED). The investigators will carry out a two-phase study to systematically characterize individual mechanisms of treatment (Phase I: N=900) and then test the efficacy of each treatment module (Phase II: N=240 drawn from Phase I) compared to the current gold-standard treatment (Cognitive Behavioral Therapy Enhanced: CBT-E). The study goals are to (1) characterize the prevalence of T-NIPT-ED precision treatment mechanisms and medical and psychological comorbidities (e.g., obesity; depression), individual disease burden (e.g., disability), SDOH (e.g., food insecurity), and public health outcomes (e.g., service utilization) specific to these mechanisms, (2) identify if personalized target mechanisms improve when matched to evidence-based treatment modules of T-NIPT-ED and (3) test if change in T-NIPT-ED is associated with improved outcomes (vs CBT-E), including ED outcomes, comorbidities, disease burden, and public health outcomes and if these outcomes are moderated
Primary Outcome
Eating Disorder Examination Questionnaire 6.0 (EDE-Q) will be used to measure change in eating disorder symptoms. The EDEQ has a minimum global score of 0 and a maximum global score of 132. Higher scores indicate more severe eating pathology.
Conditions Studied
Interventions
- BEHAVIORAL Transdiagnostic Network Informed Personalized Treatment
- BEHAVIORAL Enhanced Cognitive Behavioral Therapy for Eating Disorders
Study Locations (1)
Kentucky
- Eating Anxiety Laboratory and Clinic - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2024-01-21 |
| Est. Completion | 2029-02 |
| Phase | NA |
What NCT06208605 shows while recruiting
NCT06208605 is an interventional study that assigns participants to a tested intervention. The registered 320 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 314-participant average among 37 other Eating Disorders trials with a reported enrollment target.
The record links to 1 condition, with Eating Disorders appearing as the primary indexed condition, and to 2 interventions - of which Transdiagnostic Network Informed Personalized Treatment is the first listed.
NCT06208605 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT06208605 about?
NCT06208605 is a clinical study titled "Innovations in Personalizing Treatment Study". Eating disorders (EDs) are serious mental illness: someone dies of an ED every 52 minutes. EDs are highly related to a host of negative outcomes, including public health and individual disease burden, medical and psychological comorbidities, and social determinants of health (SDOH). Treatment respon...
What is the current status of trial NCT06208605?
This trial is currently recruiting. It is a NA study. The enrollment target is 320 participants. The study started on 2024-01-21. Estimated completion is 2029-02.
What conditions does trial NCT06208605 study?
This clinical trial studies the following conditions: Eating Disorders.
What interventions are being tested in trial NCT06208605?
The interventions under investigation include: Transdiagnostic Network Informed Personalized Treatment (BEHAVIORAL), Enhanced Cognitive Behavioral Therapy for Eating Disorders (BEHAVIORAL).
Who is sponsoring clinical trial NCT06208605?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06208605 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Eating Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06208605's enrollment target sits among peer trials
320 6th of 37 higher than 32 of 37 other Eating Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Eating Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Facing Eating Disorder Fears for Anorexia Nervosa
RECRUITING · NA
-
Targeting Transdiagnostic Self-regulatory Factors and Eating Disorder Pathology Among Adults With BInge-spectrum Eating disOrders: A mHEALTH Interoceptive Exposure Intervention (the Bio-HEALTH Study)
RECRUITING · NA
-
Targeting Social Function in Anxiety and Eating Disorders
RECRUITING · NA
-
Diabetes Body Project 2
RECRUITING · NA
-
Acceptability and Feasibility of a Single-Session Online Parent-Focused Intervention Targeting Child Body Image Development
RECRUITING · NA
-
Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02763683 · 320 participants
Investigations of Dementia in Parkinson Disease
- NCT03331198 · 320 participants · Phase 1
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
- NCT03458832 · 320 participants
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
- NCT03551951 · 320 participants
Tumor Cell and DNA Detection in the Blood, Urine, and Bone Marrow
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI